Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06477640 · ClinicalTrials.gov registry record · NA
Home Rehabilitation Improves Cardiac Effort in Pulmonary Arterial Hypertension
A NA study of Pulmonary Arterial Hypertension PAH, sponsored by University of Rochester.
- Recruiting
- Registry status
- NA
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT06477640: Recruiting NA study of Pulmonary Arterial Hypertension PAH, sponsored by University of Rochester.
NCT06477640 is a NA study of Pulmonary Arterial Hypertension PAH that is actively recruiting participants, run by University of Rochester. The registered enrollment target is 55 participants, above the 37-participant average among 5 other Pulmonary Arterial Hypertension PAH trials with a reported enrollment target (49% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06477640, a NA study of Pulmonary Arterial Hypertension PAH, is actively recruiting participants, sponsored by University of Rochester.
- RECRUITING
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate whether a home rehabilitation program for patients diagnosed with Pulmonary Arterial Hypertension (PAH) will decrease Cardiac Effort (number of heart beats used during 6-minute walk test/walk distance) and improve quality of life. Ultimately, this information could help improve the management of patients with PAH.
Primary Outcome
Cardiac effort is the number of heartbeats used during the a six minute walk test divided by walk distance
Conditions Studied
Interventions
- BEHAVIORAL Exercise
- BEHAVIORAL Standard of Care
Study Locations (1)
New York
- University of Rochester Medical Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2024-07-29 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What NCT06477640 shows while recruiting
NCT06477640 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, above the 37-participant average among 5 other Pulmonary Arterial Hypertension PAH trials with a reported enrollment target (49% higher).
The record links to 1 condition, with Pulmonary Arterial Hypertension PAH appearing as the primary indexed condition, and to 2 interventions - of which Exercise is the first listed.
NCT06477640 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06477640 about?
NCT06477640 is a clinical study titled "Home Rehabilitation Improves Cardiac Effort in Pulmonary Arterial Hypertension". The purpose of this study is to evaluate whether a home rehabilitation program for patients diagnosed with Pulmonary Arterial Hypertension (PAH) will decrease Cardiac Effort (number of heart beats used during 6-minute walk test/walk distance) and improve quality of life. Ultimately, this information...
What is the current status of trial NCT06477640?
This trial is currently recruiting. It is a NA study. The enrollment target is 55 participants. The study started on 2024-07-29. Estimated completion is 2026-12-31.
What conditions does trial NCT06477640 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension PAH.
What interventions are being tested in trial NCT06477640?
The interventions under investigation include: Exercise (BEHAVIORAL), Standard of Care (BEHAVIORAL).
Who is sponsoring clinical trial NCT06477640?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06477640 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension PAH
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Intravenous ZMA001 in Healthy Subjects
RECRUITING · Phase 1
-
A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension
RECRUITING · Phase 1
-
PAH Exercise Study
RECRUITING · Phase 3
-
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
RECRUITING · Phase 2
-
ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI